Zurich | Switzerland
| Investor Type | Firm |
| Type of Fund | VC |
| Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Oncology • Pharmaceutical (& Medicine) |
| Stages | Seed, Series A, Series B |
| Investing | Switzerland |
| Investment Range | $100,000 - $5,000,000 |
| Investment Sweet Spot | $1,500,000 |
| Assets Under Management | $205,000,000 |
About The Fund
Pureos Bioventures is a venture capital firm based in Zurich, Switzerland, specializing in investments in private innovative drug development companies. They focus on the next generation of biological drugs and drug formats to impact patients' lives by advancing innovative treatments for severe diseases. Their portfolio includes companies developing therapeutics for severe diseases and conditions. Investment interests span across a range of therapeutic areas, including oncology, antibody drug conjugates, clinical-stage biopharmaceuticals for cancer and fibrotic diseases, recombinant human alkaline phosphatase treatments, drugs for heart failure, next-generation antibody-drug conjugates for cancer treatment, precision treatments for neuroendocrine cancers, gene therapies for neurological diseases, precision monoclonal antibodies, T-cell receptor (TCR) therapies, and regenerative therapies for the eye and central nervous system. The firm backs teams with development programs that make a true difference. Investments are geared towards companies in stages such as Seed, Series A, and Series B, with a sweet spot of $1,500,000, and a general investment range between $100,000 and $5,000,000. The firm's assets under management amount to $205,000,000. They pride themselves on a versatile team composed of venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers. Pureos Bioventures' approach is driven by a passion for biotech start-ups, innovation, and the development of new and better medicines. Additionally, their investment decisions are influenced by objectives including developing transformative and disruptive therapies, advancing clinical programs with the potential to significantly improve patient outcomes, and supporting novel biopharmaceutical approaches. The firm is involved in not only funding but also in providing strategic advisory services and networking opportunities to accelerate the development and bring innovations to market.
Pureos Bioventures's investments on record
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
e
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 85 Great Portland St.
- London, U.K.
- contact@angelspartners.com
